Search results for "CONTINUA"

showing 10 items of 362 documents

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm…

2020

Background and objectives: Current psoriasis guidelines do not usually include recommendations about first line classical or biologic treatment. The objectives of this study were: to describe shifts in the prescription of the first biological treatment, and to compare treatment withdrawal and rates of adverse events over ten years. Material and methods: Biobadaderm registry was analyzed to describe: first biological prescription in bio-naive patients, adverse events rate and reasons for drug withdrawal comparing three periods of time (2008-2010, 2011-2014, 2015-2018). Results: Anti-TNF drugs were the most prescribed biological drug from 2008 to 2010. Ustekinumab has become the most prescrib…

Drugmedicine.medical_specialtyHistologyBiologicmedia_common.quotation_subjectDiscontinuationDermatologyBiologic treatmentPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciencesDrug withdrawal0302 clinical medicinePsoriasisUstekinumabTrendmedicinePsoriasisMedical prescriptionIntensive care medicineAdverse effectmedia_commonbusiness.industryBiobadadermmedicine.diseaseDiscontinuationTreatment030220 oncology & carcinogenesisbusinessmedicine.drug
researchProduct

5PSQ-096 Hazard vulnerability analysis to evaluate the risk of drug shortages according to therapeutic class

2020

Background and importance Drug shortages are a critical challenge for the public health system, as highlighted by EAHP’s position paper. They have a negative impact on quality and efficiency of patient care. Aim and objectives The aim of our study was the application of a revised hazard vulnerability analysis (HVA) to assess which therapeutic classes of drugs are at greatest risk of shortages. Material and methods In September 2019, we analysed the drugs present in our hospital therapeutic formulary and checked which ones were included in the Italian Medicines Agency shortages list: 43 drugs were found. For each drug, we assigned a score using a revised HVA which consists of three macro are…

Drugmedicine.medical_specialtybusiness.industryPublic healthmedia_common.quotation_subjectLorazepamTazobactamDiscontinuationPneumococcal vaccineEnvironmental healthmedicineFormularybusinessDidanosinemedicine.drugmedia_commonSection 5: Patient Safety and Quality assurance
researchProduct

797 Infliximab in the Treatment of Pediatric Ibd: A Single Centre Experience

2010

Background and aims: The biological treatment of IBD acts on different stages of immunophysiopathological processes of the disease. We describe evolution and clinical response to Infliximab in paediatric patients affected by IBD diagnosed and followed at our centre. Methods: In the last triennial period at our Department of Paediatrics in Palermo 53 infusions of Infliximab were administrated to our patients affected by severe forms of IBD. All patients but one were affected by several forms of CD. Only one child was affected by U.C. associated to pyoderma gangrenosum. The total number of infusions were administrated according the ACCENT 1 study at a dose of 5 mg/Kg. All the infusions were p…

Drugmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectDiseasemedicine.diseaseInfliximabDiscontinuationSingle centreTolerabilityInternal medicinePediatrics Perinatology and Child HealthmedicinebusinessPyoderma gangrenosummedia_commonPaediatric patientsmedicine.drugPediatric Research
researchProduct

Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature.

2018

Objectives To review the available evidence concerning the possibility of discontinuing and/or tapering the dosage of TNF inhibitors (TNFi) in RA patients experiencing clinical remission or low disease activity. Methods A systematic review of the literature concerning the low dosage and discontinuation of TNFi in disease-controlled RA patients was performed by evaluation of reports published in indexed international journals (Medline via PubMed, EMBASE), in the time frame from 8 April 2013 to 15 January 2016. Results We analysed the literature evaluating the efficacy and the safety of two different strategies using TNFi, decreasing dosage or discontinuation, in patients experiencing clinica…

Drugmedicine.medical_specialtymedia_common.quotation_subjectMEDLINEArthritisEtanerceptDose-Response RelationshipArthritis Rheumatoid03 medical and health sciences0302 clinical medicineRheumatologyRheumatoidInternal medicinemedicineAdalimumabHumansPharmacology (medical)030212 general & internal medicinemedia_common030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisRemission Inductionmedicine.diseaseRheumatologyAntirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Humans; Remission Induction; Tumor Necrosis Factor-alpha; Rheumatology; Pharmacology (medical)DiscontinuationRheumatoid arthritisAntirheumatic AgentsDrugbusinessmedicine.drugRheumatology (Oxford, England)
researchProduct

Cautionnement. Plan de continuation, Délai consenti par un créancier dans le cadre de l'article 24 de la loi de 1985, Impossibilité pour la caution d…

1992

International audience; (Com. 28 mai 1991, Casas c/ Banque Nationale de Paris)

Débiteur principal[SHS.DROIT]Humanities and Social Sciences/LawRedressement et liquidation judiciaires[SHS.DROIT] Humanities and Social Sciences/LawDélai consenti au débiteurPlan de continuationCAUTIONNEMENT
researchProduct

Evaluando la evaluación continua

2013

El principal proposito de este trabajo es analizar el impacto que tienen las nuevas metodologias educativas sobre los resultados del aprendizaje. En el mismo se compara el efecto sobre las notas de la evaluacion tradicional, basada en una prueba final unicamente, con la evaluacion continua. Los datos utilizados para el estudio provienen de una encuesta realizada el dia del examen final.  Al ser la encuesta no anonima se ha podido combinar esta informacion con las calificaciones. El principal resultado del analisis realizado es que los alumnos que han optado por el itinerario de evaluacion continua han obtenido una mejor calificacion y, por tanto, un mejor resultado del aprendizaje. Esta mej…

EEESdocencia; macroeconomía; evaluación continua; EEES; rendimientomacroeconomíadocencia; macroeconomía;evaluación continuarendimientodocencia
researchProduct

Acceptance and Continuance Intention of Web-based Learning Technologies (WLT) Use among University Students in a Baltic Country

2006

This paper presents the acceptance and "continuance intention" of use for Web-based learning tools among University students in an Eastern European Country, namely Estonia. In this paper, we used the technology acceptance model (TAM), which was extended to include two external constructs: the technology and user characteristics. These two constructs were modeled to influence the perceived ease of use, and perceived usefulness constructs in the TAM. Further, another construct - continuance intention - in the information systems (IS) post-adoption literature was linked to the TAM. We used a sample of 72 students from four local higher educational institutions that have experience with a speci…

Eastern europeanKnowledge managementbusiness.industryInformation systemContext (language use)ContinuanceTechnology acceptance modelUsabilitybusinessAffect (psychology)PsychologyConstruct (philosophy)Information SystemsThe Electronic Journal of Information Systems in Developing Countries
researchProduct

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

2019

Abstract Background Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on the combination used. The objective of this study was to fully describe adverse events from the COLUMBUS study evaluating the most recent BRAF/MEK inhibitor combination encorafenib+binimetinib. Patients and methods Patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma were randomised to receive encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, encorafenib 300 mg on…

Encorafenib0301 basic medicineOncologyMaleCancer ResearchSkin NeoplasmsBinimetinib; Encorafenib; Melanoma; Safety; Vemurafenib;MedizinBinimetinibchemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy Protocols1306 Cancer ResearchVemurafenibMelanomaFatigueeducation.field_of_studySulfonamidesMEK inhibitorMelanomaStandard treatmentIncidence10177 Dermatology ClinicBinimetinibNauseaMiddle AgedOncology030220 oncology & carcinogenesis2730 OncologyFemaleSafetyMitogen-Activated Protein Kinasesmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtyVomitingPopulation610 Medicine & health03 medical and health sciencesInternal medicinemedicineHumanseducationAdverse effectProtein Kinase Inhibitorsbusiness.industrymedicine.diseaseDiscontinuation030104 developmental biologychemistryVemurafenibMutationBenzimidazolesCarbamatesbusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Pena illegale e poteri del giudice dell'esecuzione

2023

Costituisce ipotesi di pena illegale, rilevabile dal giudice dell'esecuzione, l'aumento di pena disposto dal giudice della cognizione in applicazione della continuazione tra il reato giudicato in Italia e altro reato satellite giudicato con sentenza emessa da uno Stato dell'Unione europea non riconosciuta nell’ordinamento italiano, posto che detto vincolo non rientra in alcuna delle ipotesi in presenza delle quali tali sentenze assumono rilevanza ai sensi dell’art. 3 d.leg. 12 maggio 2016 n. 73. I penetranti poteri del giudice dell'esecuzione si giustificano in ragione della circostanza che il principio di legalità della pena informa di sé tutto il sistema penale, sicché l’operatività della…

Esecuzione penalePoteri del giudice dell’esecuzione.Settore IUS/16 - Diritto Processuale PenalePena illegaleRiconoscimento sentenza penale stranieraReato giudicato all'estero con sentenza non riconosciuta in ItaliaContinuazione
researchProduct

Unique continuation of the normal operator of the x-ray transform and applications in geophysics

2020

We show that the normal operator of the X-ray transform in $\mathbb{R}^d$, $d\geq 2$, has a unique continuation property in the class of compactly supported distributions. This immediately implies uniqueness for the X-ray tomography problem with partial data and generalizes some earlier results to higher dimensions. Our proof also gives a unique continuation property for certain Riesz potentials in the space of rapidly decreasing distributions. We present applications to local and global seismology. These include linearized travel time tomography with half-local data and global tomography based on shear wave splitting in a weakly anisotropic elastic medium.

FOS: Physical sciencesx-ray transformSpace (mathematics)01 natural sciencesTheoretical Computer SciencePhysics - GeophysicsContinuationtomografiaClassical Analysis and ODEs (math.CA)FOS: MathematicsNormal operatorUniqueness0101 mathematicsAnisotropyMathematical PhysicsMathematicsX-ray transformgeophysicsApplied Mathematics010102 general mathematicsMathematical analysisgeofysiikkaShear wave splittingInverse problemFunctional Analysis (math.FA)Geophysics (physics.geo-ph)Computer Science ApplicationsMathematics - Functional Analysis010101 applied mathematicsMathematics - Classical Analysis and ODEsSignal ProcessingInverse Problems
researchProduct